NEW YORK – RxGenomix and Translational Software (TSI) said Tuesday that they would partner to offer a combined, pharmacist-led pharmacogenomics product that includes claims analytics, clinical decision support, and provider education.
Franklin, Tennessee-based RxGenomix is contributing its communications hub to connect pharmacies to molecular laboratories for sharing of data from laboratory information systems, electronic health records, and pharmacy information systems. The system, called RxGenomix Hub, offers clinical decision support to help pharmacists support prescribers in the interpretation of PGx reports.
TSI, headquartered in Bellevue, Washington, makes a guideline-driven knowledge platform for reporting, featuring genomic decision support and critical alerts to physicians regarding drug efficacy, toxicity, and known interactions.
"We found Translational Software (TSI) to have strict evidence-based standards for all of its guidance, and a track record of complex PGx deployments across different stakeholders that complements our continued strategy of pharmacist-led PGx capabilities," RxGenomix COO Blake Keller said in a statement. "TSI also brings the right security posture, and a flexible and collaborative partnership approach which accelerates RxGenomix's ability to deploy the most comprehensive and effective PGx offering in healthcare."
The partnership "aligns with our broader vision of continuing to democratize precision medicine and, specifically, pharmacogenetics," TSI CEO Don Rule said. "This is another example of our diversified reach as we continue to service clinical laboratories, health systems, benefit brokers, and those servicing employers in improving health outcomes via pharmacogenetic testing."
RxGenomix entered into a partnership a year ago with Coriell Life Sciences to offer a pharmacogenomics training, implementation, and management package to healthcare providers.